No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
CN Stock MarketDetailed Quotes
688363 Bloomage Biotechnology Corporation Limited
- 60.30
- -0.72-1.18%
Trading Jul 23 10:02 CST
29.05BMarket Cap45.72P/E (TTM)
61.18High60.30Low3.10KlotVolume61.01Open61.02Pre Close18.82MTurnover0.16%Turnover Ratio49.02P/E (Static)481.68MShares99.4952wk High4.10P/B11.95BFloat Cap50.2252wk Low73.22Limit Up198.18MShs Float313.48Historical High48.82Limit Down1.44%Amplitude50.22Historical Low0.61Dividend TTM60.68Avg Price2.01KlotAsk1.01%Div YieldTTM100Lot Size907.03lotBid
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Bloomage Biotechnology Corporation Limited (688363.SH) has repurchased a total of 3.3155 million shares, costing 220 million yuan.
Bloomage Biotechnology Corporation Limited (688363.SH) announced that as of June 28, 2024, the company has cumulatively repurchased company shares...
Bloomage BioTechnology Corporation Limited's (SHSE:688363) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Bloomage BioTechnology (SHSE:688363) has had a rough month with its share price down 3.6%. However, a closer look at its sound financials might cause you to think again. Given that fundamentals usua
CITIC Securities: the collagen industry's prosperity continues with significant growth among various leading companies, and there is ample potential for the future.
According to the Zhitong Finance APP, Citic Securities research report believes that the sales of restructured collagen products have been excellent, with brands such as Weweima, Kelifu, and Viyimi performing well this year.
As of May 31st, 2024, there were 35,186 shareholders in Bloomage Biotechnology Corporation Limited (688363.SH).
Bloomage Biotechnology Corporation Limited (688363.SH) stated on the investor interaction platform on June 4th that as of May 31, 2024, the number of shareholders in the company was 35,186.
Here's Why Bloomage BioTechnology (SHSE:688363) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' It's only n
Huaxi Biotech (688363.SH): The company's medical and aesthetic business developed well in the first quarter and maintained rapid growth
Gelonghui, May 24 | Huaxi Biotech (688363.SH) said on the investor interactive platform that the company's medical and aesthetic business developed well in the first quarter of 2024 and still maintained rapid growth.
Comments
Bloomage BioTechnology's solid financials and high ROE suggest a bright future, despite recent share price drop. Its efficient profit use and shareholder profit-sharing commitment are encouraging. Analysts predict continued earnings expansion.
Bloomage BioTechnology Corporation Limited's (SHSE:688363) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong? 1
Bloomage BioTechnology's high P/E ratio could face pressure due to weak earnings outlook and slower growth. Overly bullish investors refusing to sell at current prices may face future disappointment.
Core point
1. In the past three years, China's medical beauty industry has undergone earth-shaking changes, and non-surgical products occupy the mainstream
2. The brand is a marketing tool and a social contract for the legal entity to face society. Last year, it began to issue documents on supervising medical aesthetics, focusing on doctors' qualifications, marketing, and the capabilities of three types of ...
1. In the past three years, China's medical beauty industry has undergone earth-shaking changes, and non-surgical products occupy the mainstream
2. The brand is a marketing tool and a social contract for the legal entity to face society. Last year, it began to issue documents on supervising medical aesthetics, focusing on doctors' qualifications, marketing, and the capabilities of three types of ...
International beauty giants released their financial reports
$L'OREAL(LRLCF.US$ $Estee Lauder(EL.US$ $Shiseido (ADR)(SSDOY.US$
①China's overall performance is poor, with only L'Oreal's positive growth, behind the reflection of organizational efficiency and brand matrix perfection differences.
②Effective skincare continues to overgrow, perfume demand explodes, and wash care upgrade is ready to take ...
$L'OREAL(LRLCF.US$ $Estee Lauder(EL.US$ $Shiseido (ADR)(SSDOY.US$
①China's overall performance is poor, with only L'Oreal's positive growth, behind the reflection of organizational efficiency and brand matrix perfection differences.
②Effective skincare continues to overgrow, perfume demand explodes, and wash care upgrade is ready to take ...
7
2022 is a year full of variables in the beauty market.
1. Epidemic + consumption off-season
National Bureau of Statistics January-November total cosmetics retail sales of 365.2 billion yuan, down 3.1% year-on-year, August-November is a continuous negative growth.
Two landmark events in the year's first half, the ebb of beauty collection stores and the cold of 618, foreshadowed the standard pressure at...
1. Epidemic + consumption off-season
National Bureau of Statistics January-November total cosmetics retail sales of 365.2 billion yuan, down 3.1% year-on-year, August-November is a continuous negative growth.
Two landmark events in the year's first half, the ebb of beauty collection stores and the cold of 618, foreshadowed the standard pressure at...
Read more
Analysis
Price Target
No Data
Heat List
CN
Overall
Symbol
Latest Price
%Chg